Ricerca avanzata

Home > Riviste > Minerva Ginecologica > Fascicoli precedenti > Minerva Ginecologica 2015 Dicembre;67(6) > Minerva Ginecologica 2015 Dicembre;67(6):557-74



Rivista di Ostetricia e Ginecologia

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index

Periodicità: Bimestrale

ISSN 0026-4784

Online ISSN 1827-1650


Minerva Ginecologica 2015 Dicembre;67(6):557-74


Drug therapy for overactive bladder

Izett M., Zacchè M., Giarenis I., Robinson D., Cardozo L.

Department of Urogynecology, King’s College Hospital NHS Foundation Trust, London, UK

Overactive bladder is a syndrome with a significant worldwide prevalence and economic impact on health resources. With ageing populations, the health burden of this condition that is more common in older people, is likely to increase. Following conservative therapies, medical management of overactive bladder is the mainstay of treatment, usually with antimuscarinic therapy. However, adherence is poor either due to adverse events or lack of efficacy of therapy. There have been recent developments that include a β3-adrenoreceptor agonist and intradetrusor botulinum toxin, both of which are increasingly supported by a robust evidence base. Additionally there are emerging combination therapies and novel target agents that aim to treat this troubling syndrome. Alternative modes of delivery for existing therapies are also being explored with a view to improving adherence and efficacy. This article aims to outline the evidence base for existing and novel therapies as well as inform readers of emerging therapeutic options.

lingua: Inglese


inizio pagina